SpyGlass Pharma

Update in progress

SGP (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

SpyGlass Pharma, Inc. is a biopharmaceutical company focused on treatments and drug delivery for chronic eye conditions. It is developing the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which places drug pads on an intraocular lens to be implanted during cataract surgery and help reduce elevated intraocular pressure. The company also works on a non-IOL, ring-shaped, sustained-release bimatoprost implant. Formerly SpyGlass Ophthalmics, it changed its name in 2021, was incorporated in 2019, and is based in Aliso Viejo, California.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive